FDA Grants Priority Review to Intravenous Treatment of COVID-19 in Hospitalized Adults
FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.
Roche announced on April 4, 2022 that FDA has accepted the company’s supplemental Biologics License Application (sBLA) and has granted Priority Review for Actemra/RoActemra intravenous for the treatment of COVID-19 in hospitalized adults. The treatment is for patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Actemra/RoActemra is currently approved for the treatment of COVID-19 in 16 countries, including the European Union. According to Roche, more than one million hospitalized patients with COVID-19 have been treated with Actemra/RoActemra worldwide. The treatment received Emergency Use Authorization from FDA in June 2021 and prequalification by the World Health Organization (WHO) for patients with severe or critical COVID-19 in February 2022. A decision on FDA approval is expected in the second half of 2022.
Roche is also aiming to establish a comprehensive access approach to improving the availability of its COVID-19 medicines around the world. The company is specifically focusing on providing Actemra/RoActemra via WHO and partners of the Access to COVID-19 Tools Accelerator (ACT-A) Initiative to low and middle-income countries, as well as implementing an international differentiated pricing strategy designed to improve accessibility and affordability worldwide.
“The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalized with COVID-19,” said Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche, in a press release. “More than one million people with severe or critical COVID-19 have already been treated with Actemra/RoActemra worldwide, demonstrating the important role of this medicine in the fight against the pandemic.”
Source: Roche
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
